OSE Immunotherapeutics - Steady progress on all fronts
OSE Immunotherapeutics (OSE) and its three pharma partners have made progress with all key clinical and preclinical assets. The final analysis of...
2 Views
OSE Immunotherapeutics - Solid new details from Step 1 of Tedopi Ph III trial
On 21 September 2020, OSE presented additional data from step one of the Phase III Atalante 1 trial at the virtual ESMO conference. This followed...
159 Views
OSE Immunotherapeutics - Encouraging data from novel preclinical projects
OSE has a well-balanced R&D pipeline in terms of technology and asset stage (from discovery to Phase III). At the American Association of...
74 Views
OSE Immunotherapeutics - Positive Tedopi step 1, rethinking its future
On 1 April 2020, OSE announced that the primary endpoint was met in the predefined step 1 analysis of the Phase III Atalante 1 trial with OSE’s...
505 Views
OSE Immunotherapeutics - Progress with key R&D assets
OSE has a well-balanced R&D pipeline in terms of asset stage and technology. In the near term, much of the focus is on Tedopi, an off-the-shelf...
642 Views